Abstract
Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Graphical Abstract
Current Drug Targets
Title:Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Volume: 19 Issue: 11
Author(s): Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
Affiliation:
- Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117,United States
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Abstract: Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Export Options
About this article
Cite this article as:
Akagi Daisuke *, Hoshina Katsuyuki , Watanabe Toshiaki and Conte S. Micheal, Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666171013101815
DOI https://dx.doi.org/10.2174/1389450118666171013101815 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Exploring the use of Estrogen & Progesterone Replacement Therapy in Subarachnoid Hemorrhage
Current Drug Safety Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Doxycycline Inhibition of Abdominal Aortic Aneurysm Growth - A Systematic Review of the Literature
Current Vascular Pharmacology Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Chest Pain in Children
Current Pediatric Reviews Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Drug Eluting Stents and Beyond
Current Pharmaceutical Design Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Inflammation & Allergy - Drug Targets (Discontinued) Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews